References

Regulatory T cells in solid organ transplantation

10.1002/cti2.1099 · ExternalCitation · doi-reference

Successful use of nonantigen-specific immunoadsorption with antihuman Ig-columns in kidney graft antibody-mediated rejection

10.1002/jca.21779 · ExternalCitation · doi-reference

Impact of intra-patient variability of tacrolimus on allograft function and CD4 + /CD8 + ratio in kidney transplant recipients: a retrospective single-center study

10.1007/s11096-024-01726-w · ExternalCitation · doi-reference

Searching for the minimum required dose of daratumumab to induce effective plasma cell depletion in antibody-mediated rejection of the kidney graft: a case report

10.1007/s40620-024-02182-5 · ExternalCitation · doi-reference

The Banff 2022 kidney meeting report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics

10.1016/j.ajt.2023.10.016 · ExternalCitation · doi-reference

Improving the histologic detection of donor-specific antibody-negative antibody-mediated rejection in kidney transplants

10.1016/j.ajt.2025.08.029 · ExternalCitation · doi-reference

Partial endothelial-to-mesenchymal transition associates with endothelial human leukocyte antigen II expression and precedes the development of de novo donor-specific anti-human leukocyte antigen antibodies in kidney recipients experiencing a delayed graft function

10.1016/j.ajt.2025.09.026 · ExternalCitation · doi-reference

On the relative relevance of donor-derived cell-free DNA and urinary chemokines as noninvasive biomarkers for the diagnosis of kidney allograft rejection

10.1016/j.ajt.2026.03.021 · ExternalCitation · doi-reference

Enhanced detection of antibody-mediated rejection using the tissue-based Molecular Microscope Diagnostic System (MMDx)

10.1016/j.healun.2025.12.002 · ExternalCitation · doi-reference

A Banff-based histologic chronicity index is associated with graft loss in patients with a kidney transplant and antibody-mediated rejection

10.1016/j.kint.2022.09.030 · ExternalCitation · doi-reference

Proteomic landscape of the extracellular matrix in the fibrotic kidney

10.1016/j.kint.2023.01.021 · ExternalCitation · doi-reference

Single-cell spatial transcriptomics reveal intraglomerular cell activation and ligand-receptor relationships in chronic, active antibody mediated rejection

10.1016/j.kint.2025.08.042 · ExternalCitation · doi-reference

The role of circulating T follicular helper cells in kidney transplantation

10.1016/j.trim.2021.101459 · ExternalCitation · doi-reference

Effect of C1q-binding donor-specific anti-HLA antibodies on the clinical outcomes of patients after renal transplantation: A systematic review and meta-analysis

10.1016/j.trim.2022.101566 · ExternalCitation · doi-reference

Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials

10.1016/s0140-6736(20)30167-7 · ExternalCitation · doi-reference

The role of complement in the early immune response to transplantation

10.1038/nri3225 · ExternalCitation · doi-reference

The role of complement in antibody-mediated rejection in kidney transplantation

10.1038/nrneph.2012.212 · ExternalCitation · doi-reference

Long-lived autoreactive plasma cells drive persistent autoimmune inflammation

10.1038/nrrheum.2011.1 · ExternalCitation · doi-reference

Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants

10.1038/s41467-019-13113-5 · ExternalCitation · doi-reference

The multifaceted role of complement in kidney transplantation

10.1038/s41581-018-0071-x · ExternalCitation · doi-reference

Translating B cell immunology to the treatment of antibody-mediated allograft rejection

10.1038/s41581-023-00791-0 · ExternalCitation · doi-reference

Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant

10.1056/nejm199912023412303 · ExternalCitation · doi-reference

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection

10.1056/nejmoa035717 · ExternalCitation · doi-reference

Antibody-mediated rejection of solid-organ allografts

10.1056/nejmra1802677 · ExternalCitation · doi-reference

Memory B cells and long-lived plasma cells in AMR

10.1080/0886022x.2022.2128374 · ExternalCitation · doi-reference

CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation

10.1080/13543784.2025.2463092 · ExternalCitation · doi-reference

Chimeric HLA antibody receptor T cell therapy for humoral transplant rejection

10.1093/ndt/gfae160 · ExternalCitation · doi-reference

Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: A randomized trial

10.1093/ndt/gfae282 · ExternalCitation · doi-reference

Antibody-mediated rejection—treatment standard

10.1093/ndt/gfaf097 · ExternalCitation · doi-reference

Antibody-mediated rejection in ABO-incompatible kidney transplantation

10.1093/ndt/gfaf224 · ExternalCitation · doi-reference

Biopsy-based transcriptomics in the diagnosis of kidney transplant rejection

10.1097/mnh.0000000000000974 · ExternalCitation · doi-reference

Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts

10.1097/tp.0000000000000184 · ExternalCitation · doi-reference

One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial

10.1097/tp.0000000000000958 · ExternalCitation · doi-reference

Prognostic value of the persistence of C1q-binding anti-HLA antibodies in acute antibody-mediated rejection in kidney transplantation

10.1097/tp.0000000000002002 · ExternalCitation · doi-reference

The treatment of antibody-mediated rejection in kidney transplantation

10.1097/tp.0000000000002049 · ExternalCitation · doi-reference

Recommended treatment for antibody-mediated rejection after kidney transplantation: The 2019 expert consensus from the Transplantion Society Working Group

10.1097/tp.0000000000003095 · ExternalCitation · doi-reference

CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection

10.1097/tp.0000000000003247 · ExternalCitation · doi-reference

The problem of subclinical antibody-mediated rejection in kidney transplantation

10.1097/tp.0000000000003543 · ExternalCitation · doi-reference

Cellular and molecular crosstalk of graft endothelial cells during AMR: Effector functions and mechanisms

10.1097/tp.0000000000003741 · ExternalCitation · doi-reference

Anti-interleukin-6 antibody clazakizumab in antibody-mediated renal allograft rejection: Accumulation of antibody-neutralized interleukin-6 without signs of proinflammatory rebound phenomena

10.1097/tp.0000000000004285 · ExternalCitation · doi-reference

Extracorporeal photopheresis reduces fibrotic and inflammatory transcriptomic biological marker of chronic antibody-mediated kidney rejection

10.1097/txd.0000000000001587 · ExternalCitation · doi-reference

Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: Final results from BENEFIT-EXT, a phase III randomized study

10.1111/ajt.13830 · ExternalCitation · doi-reference

Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: Results of a randomized double-blind placebo-controlled pilot study

10.1111/ajt.13871 · ExternalCitation · doi-reference

Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: A pilot randomized controlled trial

10.1111/ajt.14001 · ExternalCitation · doi-reference

The Banff 2017 kidney meeting report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials

10.1111/ajt.14625 · ExternalCitation · doi-reference

De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies

10.1111/ajt.14721 · ExternalCitation · doi-reference

Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies

10.1111/ajt.15175 · ExternalCitation · doi-reference

Sensitization in transplantation: Assessment of risk (STAR) 2019 working group meeting report

10.1111/ajt.15937 · ExternalCitation · doi-reference

Extracellular vesicles derived from patients with antibody-mediated rejection induce tubular senescence and endothelial to mesenchymal transition in renal cells

10.1111/ajt.17097 · ExternalCitation · doi-reference

Plasma cell biology: Foundations for targeted therapeutic development in transplantation

10.1111/imr.13011 · ExternalCitation · doi-reference

Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients

10.1111/j.1600-6143.2011.03757.x · ExternalCitation · doi-reference

Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence

10.1111/j.1600-6143.2011.03840.x · ExternalCitation · doi-reference

Bortezomib alleviates antibody‐mediated rejection in kidney transplantation by facilitating Atg5 expression

10.1111/jcmm.16998 · ExternalCitation · doi-reference

Carfilzomib-based antibody mediated rejection therapy in pediatric kidney transplant recipients

10.1111/petr.14534 · ExternalCitation · doi-reference

Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial

10.1136/bmj.m3734 · ExternalCitation · doi-reference

Pretransplant donor-specific anti-HLA antibodies and the risk for rejection-related graft failure of kidney allografts

10.1155/2020/5694670 · ExternalCitation · doi-reference

Elevated number of IL-21+ TFH and CD86+CD38+ B cells in blood of renal transplant recipients with AMR under conventional immuno-suppression

10.1177/20587384211048027 · ExternalCitation · doi-reference

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

10.1182/blood.2024025454 · ExternalCitation · doi-reference

Can regulatory T cells improve outcomes of sensitised patients after HLA-Ab incompatible renal transplantation: study protocol for the Phase IIa GAMECHANgER-1 trial

10.1186/s12882-023-03157-7 · ExternalCitation · doi-reference

Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study

10.1186/s12882-025-03951-5 · ExternalCitation · doi-reference

Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)

10.1186/s13063-024-08020-0 · ExternalCitation · doi-reference

Detection of infiltrating fibroblasts by single-cell transcriptomics in human kidney allografts

10.1371/journal.pone.0267704 · ExternalCitation · doi-reference

High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine

10.15585/mmwr.mm6627e1 · ExternalCitation · doi-reference

Non-complement–binding de novo donor-specific anti-HLA antibodies and kidney allograft survival

10.1681/asn.2014040326 · ExternalCitation · doi-reference

Markers of endothelial-to-mesenchymal transition

10.1681/asn.2014070679 · ExternalCitation · doi-reference

A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection

10.1681/asn.2017070818 · ExternalCitation · doi-reference

Extracellular matrix injury of kidney allografts in antibody-mediated rejection: A proteomics study

10.1681/asn.2020030286 · ExternalCitation · doi-reference

Missing self-induced activation of NK cells combines with non-complement-fixing donor-specific antibodies to accelerate kidney transplant loss in chronic antibody-mediated rejection

10.1681/asn.2020040433 · ExternalCitation · doi-reference

CRISPR/Cas9-engineered HLA-deleted glomerular endothelial cells as a tool to predict pathogenic non-HLA antibodies in kidney transplant recipients

10.1681/asn.2021050689 · ExternalCitation · doi-reference

Banff human organ transplant transcripts correlate with renal allograft pathology and outcome: Importance of capillaritis and subpathologic rejection

10.1681/asn.2022040444 · ExternalCitation · doi-reference

HLA type and the effect of HLA antibodies in kidney, liver, and pancreas transplantation: A review

10.18502/ajmb.v18i1.21042 · ExternalCitation · doi-reference

Evaluation of antibodies directed against two GPCRs, anti-AT1R and anti-ETAR, on kidney transplant outcome

10.2174/1389203722666210706163149 · ExternalCitation · doi-reference

Long-term outcomes after conversion to a belatacept-based immunosuppression in kidney transplant recipients

10.2215/cjn.0000000000000411 · ExternalCitation · doi-reference

Systematic biopsy-based transcriptomics and diagnosis of antibody-mediated kidney transplant rejection in clinical practice

10.2215/cjn.0000000000000490 · ExternalCitation · doi-reference

Long-term immunosuppression management

10.2215/cjn.15040920 · ExternalCitation · doi-reference

T follicular helper cells as a new target for immunosuppressive therapies

10.3389/fimmu.2017.01510 · ExternalCitation · doi-reference

Extracellular vesicles as mediators of cellular crosstalk between immune system and kidney graft

10.3389/fimmu.2020.00074 · ExternalCitation · doi-reference

Combined immunotherapy with belatacept and BTLA overexpression attenuates acute rejection following kidney transplantation

10.3389/fimmu.2021.618737 · ExternalCitation · doi-reference

Computational prediction of biomarkers, pathways, and new target drugs in the pathogenesis of immune-based diseases regarding kidney transplantation rejection

10.3389/fimmu.2021.800968 · ExternalCitation · doi-reference

Tocilizumab and active antibody-mediated rejection in kidney transplantation: A literature review

10.3389/fimmu.2022.839380 · ExternalCitation · doi-reference

Serum soluble B cell-activating factor is a non-invasive biomarker of antibody-mediated rejection in kidney allograft with satisfactory risk stratification performance but negligible diagnostic value

10.3389/fimmu.2022.869444 · ExternalCitation · doi-reference

Chimeric antigen receptor (CAR) regulatory T-cells in solid organ transplantation

10.3389/fimmu.2022.874157 · ExternalCitation · doi-reference

Biological characteristics of HLA-G and its role in solid organ transplantation

10.3389/fimmu.2022.902093 · ExternalCitation · doi-reference

Immune surveillance and humoral immune responses in kidney transplantation – A look back at T follicular helper cells

10.3389/fimmu.2023.1114842 · ExternalCitation · doi-reference

Donor-derived cell-free DNA predicted allograft rejection and severe microvascular inflammation in kidney transplant recipients

10.3389/fimmu.2024.1433918 · ExternalCitation · doi-reference

Genetic variants of the HLA-G/LILRB1 ligand-receptor axis in donors or recipients are prognostic covariates for rejection after living kidney transplantation

10.3389/fimmu.2025.1697839 · ExternalCitation · doi-reference

Complement in kidney transplantation

10.3389/fmed.2017.00066 · ExternalCitation · doi-reference

Therapies for chronic allograft rejection

10.3389/fphar.2021.651222 · ExternalCitation · doi-reference

The role of Fc gamma receptors in antibody-mediated rejection of kidney transplants

10.3389/ti.2022.10465 · ExternalCitation · doi-reference

The clinical utility of post-transplant monitoring of donor-specific antibodies in stable renal transplant recipients: A consensus report with guideline statements for clinical practice

10.3389/ti.2023.11321 · ExternalCitation · doi-reference

Perspective for donor-derived cell-free DNA in antibody-mediated rejection after kidney transplantation: Defining context of use and clinical implications

10.3389/ti.2024.13239 · ExternalCitation · doi-reference

Targeting CD38 in antibody-mediated rejection

10.3389/ti.2025.14343 · ExternalCitation · doi-reference

Tocilizumab-based treatment of microvascular inflammation in kidney transplant recipients: A retrospective study

10.3389/ti.2025.14502 · ExternalCitation · doi-reference

The proteome of antibody-mediated rejection: From glomerulitis to transplant glomerulopathy

10.3390/biomedicines10030569 · ExternalCitation · doi-reference

The complement system in kidney transplantation

10.3390/cells12050791 · ExternalCitation · doi-reference

Treg therapy for the induction of immune tolerance in transplantation—not lost in translation

10.3390/ijms24021752 · ExternalCitation · doi-reference

The preliminary results of bortezomib used as a primary treatment for an early acute antibody-mediated rejection after kidney transplantation—a single-center case series

10.3390/jcm9020529 · ExternalCitation · doi-reference

Rejection-focused precision medicine in kidney transplantation: Biology, biomarkers, and artificial intelligence

10.3390/life16040674 · ExternalCitation · doi-reference

Critical role of complement in antibody mediated rejection in kidney transplantation

10.5500/wjt.v15.i4.108806 · ExternalCitation · doi-reference

Increased proportion of circulating T follicular helper cells and serum levels of IL-21 in antibody-mediated rejection of renal allograft

10.61882/ijkd.19.2.118 · ExternalCitation · doi-reference

Critical roles of mTOR complex 1 and 2 for T follicular helper cell differentiation and germinal center responses

10.7554/elife.17936 · ExternalCitation · doi-reference